Research Analysts Offer Predictions for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Zacks Research decreased their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research report issued on Thursday, November 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of $0.06 for the year, down from their previous forecast of $0.09. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.25) per share.

A number of other equities analysts have also weighed in on the company. Needham & Company LLC lowered their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, November 27th.

Esperion Therapeutics Stock Performance

ESPR stock opened at $2.80 on Monday. Esperion Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $3.40. The stock’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $2.16. The company has a market cap of $551.71 million, a P/E ratio of -4.38 and a beta of 0.96.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently bought and sold shares of the stock. Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after purchasing an additional 171,609 shares during the last quarter. Marshall Wace LLP grew its position in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Finally, State Street Corp increased its stake in Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.